Scott Ogg
Directeur des opérations chez ARMO BIOSCIENCES INC
Profil
Scott Ogg is currently the Vice President of Operations & Development at ARMO BioSciences, Inc. Prior to this, he worked as the Director of Project & Portfolio Management at Gilead Sciences, Inc. and as the Director of Project & Alliance Management at Arresto BioSciences, Inc. He also held positions at Nektar Therapeutics and Exelixis, Inc. as an Associate Director of Program Management and Associate Director of Research, respectively.
Dr. Ogg received his undergraduate degree from Albion College and his doctorate from Tufts University.
Postes actifs de Scott Ogg
| Sociétés | Poste | Début |
|---|---|---|
| ARMO BIOSCIENCES INC | Directeur des opérations | 01/05/2013 |
Anciens postes connus de Scott Ogg
| Sociétés | Poste | Fin |
|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/04/2013 |
Arresto BioSciences, Inc.
 Arresto BioSciences, Inc. Miscellaneous Commercial ServicesCommercial Services Arresto Biosciences, Inc. is a biotech company that develops medicines to treat cancer and fibrotic diseases by targeting extracellular matrix proteins. The company was founded by Amato Giaccia, Michael T. Longaker and Geoffrey C. Gurtner in 2007 and is headquartered in Palo Alto, California. | Corporate Officer/Principal | 01/01/2011 |
Gilead Sciences International Ltd.
 Gilead Sciences International Ltd. Other Consumer ServicesConsumer Services Founded in 1996, Gilead Sciences International Ltd. is a subsidiary of Gilead Sciences, Inc. The company is based in Cambridge, UK. Gilead Sciences International is focused on developing and delivering medications that advance the treatment of life-threatening diseases. Contact information, addresses, and directions for all of Gilead U.S. locations can be found on their website. Additionally, contact details for Gilead offices in other locations are also available. | Corporate Officer/Principal | - |
| EXELIXIS, INC. | Directeur Technique/Scientifique/R&D | - |
| NEKTAR THERAPEUTICS | Corporate Officer/Principal | - |
Formation de Scott Ogg
| Albion College | Undergraduate Degree |
| Tufts University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| EXELIXIS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Arresto BioSciences, Inc.
Arresto BioSciences, Inc. Miscellaneous Commercial ServicesCommercial Services Arresto Biosciences, Inc. is a biotech company that develops medicines to treat cancer and fibrotic diseases by targeting extracellular matrix proteins. The company was founded by Amato Giaccia, Michael T. Longaker and Geoffrey C. Gurtner in 2007 and is headquartered in Palo Alto, California. | Commercial Services |
Gilead Sciences International Ltd.
Gilead Sciences International Ltd. Other Consumer ServicesConsumer Services Founded in 1996, Gilead Sciences International Ltd. is a subsidiary of Gilead Sciences, Inc. The company is based in Cambridge, UK. Gilead Sciences International is focused on developing and delivering medications that advance the treatment of life-threatening diseases. Contact information, addresses, and directions for all of Gilead U.S. locations can be found on their website. Additionally, contact details for Gilead offices in other locations are also available. | Consumer Services |
ARMO BioSciences, Inc.
 ARMO BioSciences, Inc. Pharmaceuticals: MajorHealth Technology ARMO BioSciences, Inc. develops immunotherapy for the treatment of cancer, cardiovascular diseases, fibrosis, and inflammation. Its lead product candidate is AM0010 (pegilodecaki). The company was founded by Peter Van Vlasselaer, Martin Oft, and John B. Mumm on June 23, 2010 and is headquartered in Redwood, CA. | Health Technology |